alexa Evaluation of Pulmonary Arterial Hypertension in Patients with Direct-Acting Antiviral Medications for Hepatitis C Virus Infection A Prospective Observational Cohort Study| Abstract
ISSN: 2329-9517

Journal of Cardiovascular Diseases & Diagnosis
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Cardiovasc Dis Diagn 2019, Vol 7(6): 384

Evaluation of Pulmonary Arterial Hypertension in Patients with Direct-Acting Antiviral Medications for Hepatitis C Virus Infection ? A Prospective Observational Cohort Study

Schild DP, Roesler G, Hellige GJ, Piso RJ and Arenja N*
Department of Cardiology, Solothurner Spitaeler AG, Kantonsspital Olten, Baslerstrasse 150, 4600 Olten, Switzerland
*Corresponding Author : Arenja N, Department of Cardiology, Solothurner Spitaeler AG, Kantonsspital Olten, Baslerstrasse 150, 4600 Olten, Switzerland, Tel: 41762690143, Email: [email protected]

Received Date: Nov 13, 2019 / Accepted Date: Nov 25, 2019 / Published Date: Dec 02, 2019

Abstract

Background: Chronic hepatitis C Virus (HCV) infected patients are at higher risk for pulmonary artery hypertension (PAH) due to treatment with interferon (IFN) and ribavirin. The establishment of novel direct-acting antiviral agents (DAA) has revolutionized the HCV therapy. However, hardly any data exist evaluating the evidence of DAA-induced PAH. Therefore, the goal of this study was the evaluation of systolic pulmonary artery pressure (sPAP) in patients undergoing DAA-therapy for chronic HCV infection.

Methods: We prospectively enrolled forty-nine patients at our hospital undergoing 8-12 weeks of DAA-therapy for chronic HCV infection according to HCV genotype and co-medication. A transthoracic echocardiogram (TTE) was performed for assessing sPAP and right ventricular (RV) function before therapy, 8 weeks after DAA-therapy started and 8 weeks after completion of the total treatment regimen.

Results: Mean patient ’ s age was 51 years and 39% of the population consisted of women. Human immunodeficiency virus (HIV) coinfection was present in 12% of the population. There was no significant difference between sPAP before, during and 8 weeks after treatment (26.4 ± 6.6 mmHg, 27.6 ± 6.4 mmHg respectively 28.4 ± 5.4 mmHg, p= 0.32). The results were sex-independent in subgroup analysis. In addition, the RV function before and after treatment was normal without significant differences (fractional area change (FAC) 50.4 ± 7.3% before, 51.9 ± 6% during and 50.2 ± 7.3% after treatment, p=0.9).

Conclusion: DAA-therapy for chronic HCV infection is not associated with PAH or RV dysfunction in a follow-up of 16-20 weeks.

Keywords: Pulmonary hypertension; Cardiology; Antiviral agents; HCV medication

Citation: Schild DP, Roesler G, Hellige GJ, Piso RJ, Arenja N (2019) Evaluation of Pulmonary Arterial Hypertension in Patients with Direct-Acting Antiviral Medications for Hepatitis C Virus Infection – A Prospective Observational Cohort Study. J Cardiovasc Dis Diagn 7: 384.

Copyright: © 2019 Arenja N, et al. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 215
  • [From(publication date): 0-0 - Mar 31, 2020]
  • Breakdown by view type
  • HTML page views: 191
  • PDF downloads: 24
Top